Radboud University Nijmegen Medical Centre Department of Cognitive Neuroscience

 

Radboud University Nijmegen Medical Centre Department of Cognitive Neuroscience

Reinier Postlaan 4

Huispost 935, route 935

PO Box 9101

6500 HB Nijmegen

The Netherlands

 

 

Project leader

 
Dr. Jeffrey Glennon
 
Phone +31 (0)24-3614242
Fax +31 (0)24-3541435
E-Mail  

Project staff

 
Dr. S. Armaz Aschrafi
 
Phone +31(0)24-36-52554
E-Mail  

 

 
Dr. Geert Poelmans
 
Phone +31 (0)24-3614017
Fax +31 (0)24-3668752
E-Mail  

 

 
Ms. Katarzyna Kapusta
 
E-Mail  

Institute presentation

At the Radboud University Nijmegen Medical Centre (RUNMC), the Translational Neuropharmacology Research Group (Department of Cognitive Neuroscience) identifies and validates translational and clinical biomarkers in traits underlying neurological and psychiatric disorders. Dr. Glennon has a track record in leading and participating in (inter)national research consortia. He recently led as lead Principal Invesatigator (PI) a translational research­based (TI-­Pharma) consortium in the Netherlands focussed on preclinical and clinical studies of cannabinoids for the treatment of cognitive decline, smoking and addiction, manages a EU FP7­-funded clinical consortium (PERS) dedicated towards clinical trials in conduct disorder and leads both preclinical and business development workpackages in the EU FP7­funded translational consortium (TACTICS) on compulsivity. He is also active in the FP7-funded ADDUCE and STOP projects focussed on ADHD and suicidality respectively. Dr. Glennon served as a senior scientist in the pharmaceutical industry for 9 years prior to his appointment at RUNMC. As such, he is in a position to ensure that the output of the OPTIMISTIC consortium is fully translated in practical terms with high impact on the creation of novel treatment strategies. Together, the team members have extensive expertise in preclinical and clinical biomarkers, bioinformatics, target validation, clinical candidate selection and clinical trials.